Kircher Brigitte, Hack C Erik, Dickinson Anne M, Wang Xiao N, Oudshoorn Machteld, Sachs Annemarie, Wolbink Angela, Niederwieser Dietger, Eibl Günther J, van Houwelingen Hans C, Goulmy Els
Laboratory for Tumor and Immunobiology, Department of Hematology and Oncology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria.
J Immunol Methods. 2004 Oct;293(1-2):51-9. doi: 10.1016/j.jim.2004.06.024.
Graft-versus-host disease (GvHD) can be a major complication after allogeneic stem cell transplantation (SCT) especially when donor and recipient are unrelated. The latter serious complication, together with the growing number of available unrelated stem cell donors, demand a simple in vitro assay for functional stem cell donor selection. Activated donor cytotoxic T lymphocytes (CTLs) and natural killer cells produce granzymes (Gr) that are involved in the pathogenesis of GvHD. We measured granzymes A and B (GrA and GrB) production levels in the supernatants of 96 h pretransplant mixed lymphocyte cultures (MLC) of 26 sibling and 31 unrelated patient/donor pairs by enzyme-linked immunosorbent assay (ELISA). In detail, the GrA and GrB production levels from a selected cohort of 37 potential patient/donor pairs were correlated with relative responses (RR) of MLC and with human leukocyte antigen (HLA) class II mismatches and with the development of acute GvHD in a second, consecutive cohort of 20 sibling SCT recipients. In vitro measurement of GrA and GrB production levels significantly correlated with the RR of pretransplant MLC (r=0.492, p< or =0.01 and r=0.853, p< or =0.01, respectively) and increased with the number of HLA class II mismatches between patient and donor. Pretransplant GrA production levels were significantly associated with the in vivo development of acute GvHD grades II-IV in patients transplanted with an HLA-identical sibling donor (p< or =0.001). In conclusion, in vitro GrA and GrB production levels can be measured by a quantitative and sensitive ELISA. This novel and simple method may be used for functional selection of unrelated stem cell donors and for the identification of patients who are at risk for acute GvHD grades II-IV.
移植物抗宿主病(GvHD)可能是异基因干细胞移植(SCT)后的主要并发症,尤其是供体和受体不相关时。后一种严重并发症,以及可用的不相关干细胞供体数量的增加,需要一种简单的体外检测方法来选择功能性干细胞供体。活化的供体细胞毒性T淋巴细胞(CTL)和自然杀伤细胞产生颗粒酶(Gr),这些颗粒酶参与了GvHD的发病机制。我们通过酶联免疫吸附测定(ELISA)测量了26对同胞和31对不相关患者/供体对的移植前96小时混合淋巴细胞培养(MLC)上清液中颗粒酶A和B(GrA和GrB)的产生水平。详细地说,从37对潜在患者/供体对的选定队列中获得的GrA和GrB产生水平与MLC的相对反应(RR)、人类白细胞抗原(HLA)II类错配以及20名同胞SCT受者的第二个连续队列中的急性GvHD的发生相关。体外测量GrA和GrB产生水平与移植前MLC的RR显著相关(分别为r = 0.492,p≤0.01和r = 0.853,p≤0.01),并且随着患者和供体之间HLA II类错配数量的增加而增加。移植前GrA产生水平与接受HLA相同的同胞供体移植的患者体内急性GvHD II-IV级的发生显著相关(p≤0.001)。总之,体外GrA和GrB产生水平可以通过定量和灵敏的ELISA进行测量。这种新颖且简单的方法可用于不相关干细胞供体的功能选择以及识别有急性GvHD II-IV级风险的患者。